KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EBT (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of EBT data on record, last reported at -$50.7 million in Q4 2025.

  • For Q4 2025, EBT fell 83.7% year-over-year to -$50.7 million; the TTM value through Dec 2025 reached $82.8 million, up 157.94%, while the annual FY2025 figure was $82.8 million, 157.94% up from the prior year.
  • EBT reached -$50.7 million in Q4 2025 per EBS's latest filing, down from $57.6 million in the prior quarter.
  • Across five years, EBT topped out at $256.3 million in Q4 2021 and bottomed at -$269.8 million in Q2 2024.
  • Average EBT over 5 years is -$35.5 million, with a median of -$36.6 million recorded in 2021.
  • Peak YoY movement for EBT: tumbled 4126.32% in 2023, then surged 666.12% in 2025.
  • A 5-year view of EBT shows it stood at $256.3 million in 2021, then plummeted by 126.73% to -$68.5 million in 2022, then grew by 20.44% to -$54.5 million in 2023, then surged by 49.36% to -$27.6 million in 2024, then plummeted by 83.7% to -$50.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$50.7 million in Q4 2025, $57.6 million in Q3 2025, and -$16.8 million in Q2 2025.